QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harper, C. R. Articles by Jacobson, T. A. Search for Related Content PubMed PubMed Citation Articles by Harper, C. R. Articles by Jacobson, T. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dietary Supplements Hazardous Substances DB LINSEED OIL

---

Nutrition and Disease

Flaxseed Oil Supplementation Does Not Affect Plasma Lipoprotein Concentration or Particle Size in Human Subjects¹

² Department of Medicine, Emory University, Atlanta, GA 30303; ³ Virginia Commonwealth University, Richmond, VA 23284; and ⁴ Office of Health Promotion and Disease Prevention, Atlanta, GA 30303

^* To whom correspondence should be addressed. E-mail: charper{at}emory.edu.

-Linolenic acid (ALA) is a major dietary (n-3) fatty acid. Some clinical trials with ALA supplementation have shown reduced cardiovascular risk; however the specific cardioprotective mechanism is not known. We studied the effects of daily supplementation with ALA derived from flaxseed oil on concentrations of plasma LDL cholesterol, HDL cholesterol, intermediate density lipoprotein cholesterol, and lipid particle sizes. In a randomized double-blind trial, 56 participants were given 3 g/d of ALA from flaxseed oil in capsules (n = 31) or olive oil containing placebo capsules (n = 25) for 26 wk. Changes in plasma HDL cholesterol, LDL cholesterol, and triglyceride concentrations did not differ between the 2 groups at 26 wk. The adjusted plasma total cholesterol concentration at 26 wk was 0.45 mmol/L higher in the flaxseed oil group (5.43 ± 0.03 mmol/L) compared with the olive oil group (5.17 ± 0.07 mmol/L) (P = 0.026). ALA did not affect LDL, HDL, or IDL particle size; however, the concentrations of the large, less atherogenic LDL₁ (P = 0.058) and LDL₂ (P = 0.083) subfractions tended to be greater in the ALA group. In conclusion, ALA does not decrease CVD risk by altering lipoprotein particle size or plasma lipoprotein concentrations.

This article has been cited by other articles:

				A. Pan, D. Yu, W. Demark-Wahnefried, O. H Franco, and X. Lin Meta-analysis of the effects of flaxseed interventions on blood lipids Am. J. Clinical Nutrition, August 1, 2009; 90(2): 288 - 297. [Abstract] [Full Text] [PDF]

				J. A. Austria, M. N. Richard, M. N. Chahine, A. L. Edel, L. J. Malcolmson, C. M.C. Dupasquier, and G. N. Pierce Bioavailability of Alpha-Linolenic Acid in Subjects after Ingestion of Three Different Forms of Flaxseed J. Am. Coll. Nutr., April 1, 2008; 27(2): 214 - 221. [Abstract] [Full Text] [PDF]

				E. K. Kabagambe, M. Y. Tsai, P. N. Hopkins, J. M. Ordovas, J. M. Peacock, I. B. Borecki, and D. K. Arnett Erythrocyte Fatty Acid Composition and the Metabolic Syndrome: A National Heart, Lung, and Blood Institute GOLDN Study Clin. Chem., January 1, 2008; 54(1): 154 - 162. [Abstract] [Full Text] [PDF]